Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy ...
Plutux is not an investment adviser. Market data and AI-generated analysis are for information and education only, not investment advice. Disclaimer
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Report Q4 Fiscal 2026 Financial Results on August 25, 2026.
LQDA, FLXS, ELMD and AGX combine low beta, positive price momentum and strong fundamentals to help investors navigate market volatility.
Electromed (ELMD) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Electromed (ELMD) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Electromed is rated 'buy' due to accelerating growth, margin expansion, and a large underpenetrated bronchiectasis market. ELMD benefits from a new CMS rule and a recently approved bronchiectasis drug, both driving increased disease awareness and streamlined clinician adoption. Gross margin improved to 78.5%, operating margin rose to 20.4%, and net income reached a record $3.0 million in Q3 FY 2026.
